Human to pet in just one step.

Our proprietary PETization platform enables the rapid translation of therapeutic monoclonal antibodies (mAbs) between species.

Our mAbs are uniquely designed to be accepted by a patient's immune system as "native," a property we refer to as "100% species-specificity."

Our most advanced therapies in development are focused on treatments within two general areas: chronic pain in both dogs and cats, and inflammatory disease in dogs.

We believe biologic therapies offer significant advantages over current treatments in both these areas.

Our team of scientists and veterinarians are working to investigate further opportunities for new biologic therapies.

A diverse team of experts who are passionate about animal health.

Meet our team

Nexvet on tour

2-5 April 2015

British Small Animal Veterinary Association Conference, Birmingham, UK

12-14 May 2015

Bank of America Merrill Lynch 2015 Health Care Conference, Las Vegas, U.S.

3–6 June 2015

American College of Veterinary Internal Medicine Forum, IN, U.S.

23–24 June 2015

JMP Securities Life Sciences Conference, NYC, U.S.

2–4 July 2015

European College of Veterinary Surgeons Annual Scientific Meeting, Berlin, Germany

20-23 September 2015

Antibody Technologies and Therapeutics, Prato, Italy

16-20 January 2016

North American Veterinary Community conference, FL, U.S.

27 February - 5 March 2016

Veterinary Orthopedic Society of America Annual Conference, Sun Valley, ID, U.S.

Keep up with the transformation

Hear more — follow us on social media, browse extra content, and subscribe to our newsletter here.



01 December 2015

Nice initiative to get more lost cats home from the wonderful @oatmeal #kittyconvicts

Register for Our Newsletter

Nexvet Biopharma

Unit 5, Sragh Technology Park
Rahan Road, Tullamore
Co. Offaly, R35 FR98
P: +353 (1) 901 0339

Level 8, 31 Queen Street
Melbourne 3000
P: +61 (3) 9610 4400

United States
275 Post Street
4th Floor
San Francisco, CA 94108


Get in Touch